Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients

Toru Miyoshi, Masayuki Doi, Satoshi Hirohata, Shigeshi Kamikawa, Shinichi Usui, Hiroko Ogawa, Kosuke Sakane, Reishi Izumi, Yoshifumi Ninomiya, Shozo Kusachi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of insulin resistance (r = 0.53, p>0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein cholesterol, triglyceride, and CAVI. Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure. Multiple regression analysis revealed that the change in CAVI was independently correlated with the change in serum A-FABP. Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.

Original languageEnglish
Pages (from-to)408-413
Number of pages6
JournalHeart and Vessels
Volume26
Issue number4
DOIs
Publication statusPublished - Jul 1 2011

Keywords

  • Adipocyte
  • angiotensin II receptor antagonist
  • atherosclerosis
  • fatty acid
  • hypertension
  • inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients'. Together they form a unique fingerprint.

  • Cite this